Abiraterone-induced rhabdomyolysis: A case report

Abstract

Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.

Keywords

Abiraterone rhabdomyolysis toxicity

Get full access to this article

View all access options for this article.

References

Zimmerman

Shen

. Rhabdomyolysis. Chest 2013; 144: 1058–1065.

Product Information. Zytiga® oral tablets, abiraterone acetate oral tablets. Horsham, PA: Janssen Biotech Inc. (per FDA), 2014.

de Bono

Logothetis

Molina

. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.

Ryan

Smith

de Bono

. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148.

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Product Information. Crestor® oral tablets, rosuvastatin calcium oral tablets. Wilmington, DE: AstraZeneca Pharmaceuticals LP (per FDA), 2013.

Graham

Staffa

Shatin

. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–2590.

Rosuvastatin. In: Facts & Comparisons. St. Louis, MO: Wolters Kluwer Health. http://online.factsandcomparisons.com/MonoDisp.aspx?monoID=fandc-hcp12420&quick=289212%7c5&search=289212%7c5&isstemmed=True&NDCmapping=-1&fromTop=true#firstMatch (accessed 25 October 2015).

Product Information: PredniSONE oral tablets solution, prednisone oral tablets solution. Roxane Laboratories, Inc., Columbus, OH, 2012.

10.

Beckett RD, Rodeffer KM and Snodgrass R. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother 2012; 46: 1016–1024.

11.

Mohler JL, Armstrong AJ, Bahnson RR, et al. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: prostate cancer. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 20 July 2015).

12.

SEER Cancer Statistics Fact Sheets: Prostate Cancer. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/statfacts/html/prost.html (accessed 20 July 2015).